Hexagon Capital Partners LLC increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 74.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 138 shares of the pharmaceutical company’s stock after purchasing an additional 59 shares during the quarter. Hexagon Capital Partners LLC’s holdings in Vertex Pharmaceuticals were worth $58,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. University of Texas Texas AM Investment Managment Co. purchased a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at approximately $25,000. Arlington Trust Co LLC boosted its position in shares of Vertex Pharmaceuticals by 97.1% in the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 33 shares during the period. Annapolis Financial Services LLC purchased a new position in shares of Vertex Pharmaceuticals during the first quarter valued at $27,000. ICA Group Wealth Management LLC acquired a new position in Vertex Pharmaceuticals during the fourth quarter valued at $28,000. Finally, Fortitude Family Office LLC purchased a new stake in Vertex Pharmaceuticals in the 4th quarter worth about $30,000. Institutional investors and hedge funds own 90.96% of the company’s stock.
Insider Activity at Vertex Pharmaceuticals
In other Vertex Pharmaceuticals news, CMO Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $471.72, for a total transaction of $1,075,521.60. Following the sale, the chief marketing officer now directly owns 30,099 shares of the company’s stock, valued at $14,198,300.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Ourania Tatsis sold 2,350 shares of the company’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $439.11, for a total value of $1,031,908.50. Following the sale, the executive vice president now owns 53,523 shares of the company’s stock, valued at approximately $23,502,484.53. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CMO Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $471.72, for a total transaction of $1,075,521.60. Following the transaction, the chief marketing officer now directly owns 30,099 shares of the company’s stock, valued at $14,198,300.28. The disclosure for this sale can be found here. Insiders have sold a total of 28,366 shares of company stock valued at $13,058,787 over the last quarter. 0.20% of the stock is owned by company insiders.
Analysts Set New Price Targets
Read Our Latest Stock Analysis on VRTX
Vertex Pharmaceuticals Price Performance
Shares of VRTX stock opened at $471.25 on Tuesday. Vertex Pharmaceuticals Incorporated has a 12 month low of $335.82 and a 12 month high of $486.42. The company has a market capitalization of $121.61 billion, a P/E ratio of 30.58, a P/E/G ratio of 2.41 and a beta of 0.39. The stock has a 50 day moving average of $444.89 and a two-hundred day moving average of $426.80. The company has a current ratio of 3.50, a quick ratio of 3.29 and a debt-to-equity ratio of 0.02.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last announced its quarterly earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.66 by $1.10. The firm had revenue of $2.69 billion for the quarter, compared to analyst estimates of $2.58 billion. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. The business’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.67 EPS. As a group, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.22 EPS for the current year.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Read More
- Five stocks we like better than Vertex Pharmaceuticals
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Snowflake Stock Rebounds, Flies Higher on AI Spending
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Complete Solaria, Senti, and POET: 3 High Volume Penny Stocks
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.